Trump announces lower drug price deals with 9 pharmaceutical companies

The Trump administration announced nine major drugmakers — including Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novartis and Sanofi — have agreed to rein in U.S. Medicaid drug prices to match prices in other developed countries and to apply “most‑favored‑nation” pricing on newly launched medicines across commercial, cash, Medicare and Medicaid markets. The deal includes commitments to sell pharmacy‑ready medicines on a government-backed TrumpRx platform launching in January and donations of active pharmaceutical ingredients to a national reserve, with Bristol Myers donating Eliquis to Medicaid; the administration says it secured cooperation after threatening a 10% tariff. The measures could relieve state Medicaid budgets and reduce out‑of‑pocket costs for uninsured patients but create revenue and margin pressure for branded drugmakers; material effects on company earnings and R&D trajectories are uncertain and likely to play out over years.

Analysis

Market structure: The immediate winners are diversified, non‑U.S.‑centric pharma (Novartis NVS, Sanofi SNY, GSK) which reduce political/tariff risk and can absorb margin losses via international pricing; direct losers are U.S. revenue‑concentrated franchises with high list prices and thin net margins in Medicaid (estimate 5–15% revenue sensitivity for a typical blockbuster over 12 months). Pricing power for new launches shifts toward greater gross‑to‑net compression (MFN across payers) and will favor scale and portfolio diversification over single‑asset specialists, pressuring smaller biotech valuations. Cross‑asset: expect modest widening of high‑yield pharma credit spreads (+10–50bp over 12 months for leveraged names), slight rise in equity implied vols for affected tickers and negligible FX or commodity moves barring broader trade escalation.

Key Decisions for Investors

• Establish a 2–3% long position in NVS and a 1–2% long in GSK (6–12 month horizon). Rationale: diversified international revenue reduces US MFN exposure; target total return +8–15% if market re-rates political de‑risking. Set tactical stop-loss at -8%.
• Open a 1.5–2% short exposure to AMGN (cash short or borrow) or buy 6‑month put spreads (10–25% OTM). Rationale: high US sales concentration implies ~5–10% EPS downside risk within 12 months under MFN; put spread caps cost while preserving directional downside exposure.
• Execute a relative‑value pair: long NVS (2%) / short AMGN (1.5%) for 3–9 months to capture differential US‑exposure; rebalance if AMGN CDS widens >50bp or NVS outperforms by >10%.
• Options tactical: buy 3–6 month put spreads on GILD and AMGN (defined risk) sized to cap portfolio loss to 1–2% if downside materializes; sell 1–2 month covered calls on GSK after any Jan TrumpRx PR pop to monetize volatility. Monitor TrumpRx launch (target date: Jan 1–31) and adjust positions within 30 days of concrete pricing rules.
• Contingency trigger: if administration extends MFN or threatens tariffs to non‑compliant firms (binary within 3–6 months), increase short exposure to US‑centric drugmakers and buy pharma IG/HY protection if credit spreads exceed +75bp vs. pre‑announcement levels.